Objective: This study evaluated the efficacy of the second line chemotherapeutic regimens in persistent or recurrent epithelial ovarian cancer (EOC) by analyzing the multicenter medical data retrospectively. Methods: We reviewed clinical data of 398 persistent or recurrent EOC/PPC patients treated with second-line chemotherapy between January 2006 and December 2016. And patients were divided into three groups, platinum resistant (less than 6 months), platinum-partially sensitive (6 to 12 month) and platinum sensitive group (over 12 months), based on the first recurrence time; also the second line chemotherapeutic regimen was identified in each group. Then the duration of recurrence after the completion of second-line chemotherapy was measured and the progression-free survival (PFS) according to the second line chemotherapeutic regimen was compared. Results: The study consisted of 222 eligible and assessable patients, median age 53 years, 69 (31.1%) were platinum-resistant, 66 (29.7%) were platinum-partial sensitive and 87 (39.2%) were platinum-sensitive group. There were no significant PFS differences between regimens in both platinum-resistant and platinum-sensitive group. In platinum-partially sensitive group, however, taxane containing regimen showed significantly longer PFS than other regimens (P < 0.05). In the 6-12 month group, Median PFS of taxane containing regimen was 25 weeks, S-phase inhibitor was 15 week, topoisomerase 1inhibitor was 16 weeks, and topoisomerase 2 inhibitor was 13 weeks, respectively. Conclusion: : PFS of taxane-containing regimen is better than other regimens in platinum-partially sensitive group. There were no significant PFS differences between regimens in both platinum-resistant and platinum-sensitive group.